UNSPSC 41131712: Erythrocytic glucose-6-phosphate dehydrogenase assay

In this classification an erythrocytic glucose-6-phosphate dehydrogenase assay is a device used to measure the activity of the enzyme glucose-6-phosphate dehydrogenase or of glucose-6-phosphate dehydrogenase isoenzymes. The results of this assay are used in the diagnosis and treatment of nonspherocytic congenital hemolytic anemia or drug-induced hemolytic anemia associated with a glucose-6-phosphate dehydrogenase deficiency.

This generic device includes assays based on fluorescence, electrophoresis, methemoglobin reduction, catalase inhibition, and ultraviolet kinetics US FDA regulates Erythrocytic glucose-6-phosphate dehydrogenase assay under 21 CFR 864.736 and under FDA product code JBI.

UNSPSC 41131712 Erythrocytic glucose-6-phosphate dehydrogenase assay is a Commodity code that maps poorly to recent state and local procurement activity. The code nominally describes a specific enzymatic diagnostic assay, but the recent opportunities posted under it span drug testing, forensic analysis, employment screening, breath alcohol detection, and medical equipment procurement — none of which involve glucose-6-phosphate dehydrogenase testing. The mismatch suggests either miscoding in source data or that this Commodity sits at a tier too narrow to capture the broader drug-testing and clinical-laboratory work that state and local procurement offices are actually conducting.

Among the opportunities that do appear in the dataset, the issuing bodies are predominantly county-level criminal-justice, health, and human resources departments across Florida, Oregon, and Texas, with one municipal education system. Collin County, Texas posted an RFP for offender specimen collection and drug testing (due July 23, 2026, with an estimated contract value of $600,000 over two years plus optional renewals); Seminole County, Florida sought naloxone and drug deactivation systems; Benton County, Oregon requested urinalysis testing for a family treatment court program (due July 7, 2026); Pinellas County, Florida procured forensic drug standards for analysis validation through an informal quote; Collier County and Clay County, Florida both solicited employment physicals and drug testing; the State of Oregon issued a sole-source procurement for a clozapine assay kit; the City Colleges of Chicago requested comprehensive employment screening services including drug testing (due March 30, 2026); and the State of Nevada Department of Public Safety twice solicited breath alcohol testing equipment (Intoxilyzer 9000 units and printers, due February 12 and 17, 2026). Activity clusters in Florida and spans criminal-justice pre-trial supervision, forensic laboratories, occupational health screening, and substance-abuse treatment programs, but no single code or category appears to consolidate these disparate procurements effectively. Absent alignment between the nominal code scope and the actual recent opportunities, this Commodity shows limited decision relevance for business development targeting classical laboratory diagnostics.